Letter to the EditorOutcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
References (8)
- et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700
J Allergy Clin Immunol
(2004) - et al.
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids
J Allergy Clin Immunol
(2005) - et al.
Mepolizumab and exacerbations of refractory eosinophilic asthma
N Engl J Med
(2009)
Cited by (0)
This study was supported by the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health.
Disclosure of potential conflict of interest: C. E. Brightling has received research support from the University of Leicester and has received grants and consultancy fees paid to his institution from GlaxoSmithKline, MedImmune/AstraZeneca, Novartis, Chiesi, and Roche/Genentech. P. Bradding received mepolizumab free of charge for this study from GlaxoSmithKline and has received travel support and honoraria for lectures from GlaxoSmithKline. R. H. Green has received personal fees for honoraria, royalties, or fees for consulting, lectures, speakers' bureaus, expert testimony, employment, or other affiliations from Boehringer Ingleheim, AstraZeneca, and Novartis. A. J. Wardlaw has received research support and honoraria for advisory boards from GlaxoSmithKline; is a member of a data safety monitoring board for TEVA; and has received research support from Pfizer. H. Ortega is employed by and owns stocks in GlaxoSmithKline. I. D. Pavord has received research and travel support from and has consultant arrangements with GlaxoSmithKline; has board memberships with Almirall, AstraZeneca, Boehringer Ingelheim, 220 GlaxoSmithKline, MSD, Schering-Plough, Novartis, Dey, and Napp; has consultant arrangements with Almirall, AstraZeneca, Boehringer Ingelheim, 220 GlaxoSmithKline, MSD, Schering-Plough, Novartis, Dey, and Napp; and has received payment for lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Boston Scientific, and Aerocrine. The rest of the authors declare that they have no relevant conflicts of interest.